Read + Share
Waldmann E, Wu L, Busygina K, Altenhofer J, et al. Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in
familial dysbetalipoproteinemia (type III hyperlipidemia). PLoS One 2022;17:e0265838.
PMID: 35320320
|
 |
|
Waldmann E, Wu L, Busygina K, Altenhofer J, et al. Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in
familial dysbetalipoproteinemia (type III hyperlipidemia). PLoS One 2022;17:e0265838.
PMID: 35320320
|
|
|
|